Partnership Opportunities

New applications in sarcomas for existing cancer therapies

Identifying pathways in the development of Ewing and other sarcomas that have potential targets for existing drugs

Technology Overview

Dr. Elizabeth LawlorDr. Elizabeth Lawlor

Ewing sarcoma is a highly malignant cancer of bone and soft tissue. Although rare, it is still the second most common bone malignancy in children and adolescents. Contributors to the disease including oncogenic activity that hijacks normal stem cell programs, disrupts gene regulation through epigenetic mechanisms, and induces cells to develop along a tumorigenic rather than normal developmental path. Current treatment primarily begins with multidrug chemotherapy.

Dr. Elizabeth Lawlor’s research in Ewing sarcoma is at the nexus of translation from basic research to clinical applications. Her group focuses on making discoveries about the fundamental biology of Ewing sarcoma that have the potential to advance cancer therapy. The lab is particularly interested in repurposing existing drugs by finding pathways and pathway components that are critical to Ewing sarcoma and amenable to manipulation. The scientists in the Lawlor group are also alert for opportunities to advance the therapeutic science for other solid or blood cancers.

The Lawlor group collaborated on a study that found that small-molecule inhibition of the menin-MLL complex, which epigenetically modifies histones to regulate transcription, reduces Ewing sarcoma cell proliferation and viability in vitro and in vivo. Their investigation into the mechanism of this effect revealed the metabolic pathways most affected by menin-MLL inhibition, highlighting additional opportunities for targeted and synergistic cancer therapies.

The team also studies how the Wnt/beta-catenin signaling pathway that is critical for gene expression in development is dysregulated in Ewing sarcoma cells in a way that promotes metastasis. Using primary cells from patient tumors, Dr. Lawlor and colleagues identified genes and pathways involved in this effect, providing a biological rationale for testing targets in angiogenesis and the tumor microenvironment to reduce metastasis of Ewing and other sarcomas.

In addition to her Seattle Children’s Research Institute appointment, Dr. Lawlor is affiliated with the University of Washington and Fred Hutchinson Cancer Research Center, which has a strong history of sarcoma research, and the Seattle Cancer Care Alliance, a consortium for clinical trials. Her lab has experience with in vitro studies including tissue microarray assays with primary cells from patient tumors. They have expertise in drug testing using mouse xenograft models of sarcomas.

Dr. Lawlor has worked with biotech startup companies. She is interested in working with industry partners on using basic biological findings to identify new applications for existing drugs to improve treatment for Ewing sarcoma and other cancers.

Stage of Development

  • Pre-clinical in vitro
  • Pre-clinical in vivo

Partnering Opportunities

  • Collaborative research and development
  • Sponsored research agreement
  • Consultation agreement
  • Tissue sample access
  • Animal model access and expertise

Publications

  1. Hawkins AG, Pedersen EA, Treichel S, Temprine K, Sperring C, Read JA, Magnuson B, Chugh R, Lawlor ER. Wnt/β-catenin-activated Ewing sarcoma cells promote the angiogenic switch. JCI Insight. 2020;9;5(13):135188.
  2. Hawkins AG, Julian CM, Konzen S, Treichel S, Lawlor ER, Bailey KM. Microenvironmental factors drive tenascin C and Src cooperation to promote invadopodia formation in Ewing sarcoma. Neoplasia. 2019;21(10):1063-1072.
  3. Svoboda LK, Teh SSK, Sud S, Kerk S, Zebolsky A, Treichel S, Thomas D, Halbrook CJ, Lee HJ, Kremer D, Zhang L, Klossowski S, Bankhead AR, Magnuson B, Ljungman M, Cierpicki T, Grembecka J, Lyssiotis CA, Lawlor ER. Menin regulates the serine biosynthetic pathway in Ewing sarcomaJ Pathol. 2018;245(3):324-336.
  4. Pedersen EA, Menon R,  Bailey KM, Thomas DG, Van Noord RA, Tran J, Wang H, Qu PP, Hoering A, Fearon EA, Chugh R, Lawlor ER. Activation of Wnt/β-Catenin in Ewing sarcoma cells antagonizes EWS/ETS function and promotes phenotypic transition to more metastatic cell states. Cancer Res. 2016;76(17):5040-5053.
  5. Ban J, Aryee DNT, Fourtouna A, van der Ent W, Kauer M, Niedan S, Machado I, Rodriguez-Galindo C, Tirado OM, Schwentner R, Picci P, Flanagan AM, Berg V, Strauss S, Scotlandi K, Lawlor ER, Snaar-Jagalska E, Llombart-Bosch A, Kovar H. Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma. Cancer Res. 2014;74(22): 6578-6588.

Learn More

To learn more about partnering with Seattle Children’s Research Institute on this or other projects, email the Office of Science-Industry Partnerships